Literature DB >> 22952427

Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Samantha Gadd1, Vicki Huff, Chiang-Ching Huang, E Cristy Ruteshouser, Jeffrey S Dome, Paul E Grundy, Norman Breslow, Lawrence Jennings, Daniel M Green, J Bruce Beckwith, Elizabeth J Perlman.   

Abstract

Wilms tumors (WT) have provided broad insights into the interface between development and tumorigenesis. Further understanding is confounded by their genetic, histologic, and clinical heterogeneity, the basis of which remains largely unknown. We evaluated 224 WT for global gene expression patterns; WT1, CTNNB1, and WTX mutation; and 11p15 copy number and methylation patterns. Five subsets were identified showing distinct differences in their pathologic and clinical features: these findings were validated in 100 additional WT. The gene expression pattern of each subset was compared with published gene expression profiles during normal renal development. A novel subset of epithelial WT in infants lacked WT1, CTNNB1, and WTX mutations and nephrogenic rests and displayed a gene expression pattern of the postinduction nephron, and none recurred. Three subsets were characterized by a low expression of WT1 and intralobar nephrogenic rests. These differed in their frequency of WT1 and CTNNB1 mutations, in their age, in their relapse rate, and in their expression similarities with the intermediate mesoderm versus the metanephric mesenchyme. The largest subset was characterized by biallelic methylation of the imprint control region 1, a gene expression profile of the metanephric mesenchyme, and both interlunar and perilobar nephrogenic rests. These data provide a biologic explanation for the clinical and pathologic heterogeneity seen within WT and enable the future development of subset-specific therapeutic strategies. Further, these data support a revision of the current model of WT ontogeny, which allows for an interplay between the type of initiating event and the developmental stage in which it occurs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22952427      PMCID: PMC3431181          DOI: 10.1593/neo.12714

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  66 in total

1.  Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm.

Authors:  R Coleman Lindsley; Jennifer G Gill; Michael Kyba; Theresa L Murphy; Kenneth M Murphy
Journal:  Development       Date:  2006-08-30       Impact factor: 6.868

2.  An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.

Authors:  Miguel N Rivera; Woo Jae Kim; Julie Wells; David R Driscoll; Brian W Brannigan; Moonjoo Han; James C Kim; Andrew P Feinberg; William L Gerald; Sara O Vargas; Lynda Chin; A John Iafrate; Daphne W Bell; Daniel A Haber
Journal:  Science       Date:  2007-01-04       Impact factor: 47.728

3.  Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways.

Authors:  Colleen Cutcliffe; Donna Kersey; Chiang-Ching Huang; Yong Zeng; David Walterhouse; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

4.  Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney.

Authors:  Benjamin Dekel; Sally Metsuyanim; Kai M Schmidt-Ott; Edi Fridman; Jasmin Jacob-Hirsch; Amos Simon; Jehonathan Pinthus; Yoram Mor; Jonathan Barasch; Ninette Amariglio; Yair Reisner; Naftali Kaminski; Gideon Rechavi
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  Target genes of the WNT/beta-catenin pathway in Wilms tumors.

Authors:  Birgit Zirn; Birgit Samans; Stefanie Wittmann; Thorsten Pietsch; Ivo Leuschner; Norbert Graf; Manfred Gessler
Journal:  Genes Chromosomes Cancer       Date:  2006-06       Impact factor: 5.006

6.  Classification of malignant pediatric renal tumors by gene expression.

Authors:  Chiang-Ching Huang; Colleen Cutcliffe; Cheryl Coffin; Poul H B Sorensen; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2006-06       Impact factor: 3.167

7.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Authors:  Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

8.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation.

Authors:  Constanze Uschkereit; Noelia Perez; Carmen de Torres; Maike Küff; Jaume Mora; Brigitte Royer-Pokora
Journal:  J Med Genet       Date:  2007-06       Impact factor: 6.318

10.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

Authors:  Michael B Major; Nathan D Camp; Jason D Berndt; Xianhua Yi; Seth J Goldenberg; Charlotte Hubbert; Travis L Biechele; Anne-Claude Gingras; Ning Zheng; Michael J Maccoss; Stephane Angers; Randall T Moon
Journal:  Science       Date:  2007-05-18       Impact factor: 47.728

View more
  49 in total

Review 1.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

4.  Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.

Authors:  Hannah M Phelps; Mazin F Al-Jadiry; Natasha M Corbitt; Janene M Pierce; Bingshan Li; Qiang Wei; Raina R Flores; Hernan Correa; Stefania Uccini; Haydar Frangoul; Adel R Alsaadawi; Safaa A F Al-Badri; Amir F Al-Darraji; Raghad M Al-Saeed; Salma A Al-Hadad; Harold N Lovvorn Iii
Journal:  World J Pediatr       Date:  2018-08-28       Impact factor: 2.764

5.  Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.

Authors:  Wei Zhao; Juan Li; Ping Li; Fei Guo; Pengfei Gao; Junjie Zhang; Zechen Yan; Lei Wang; Da Zhang; Pan Qin; Guoqiang Zhao; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

6.  Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.

Authors:  Andrew J Murphy; Janene Pierce; Christian de Caestecker; Jaime Libes; David Neblett; Mark de Caestecker; Alan O Perantoni; Shunsuke Tanigawa; James R Anderson; Jeffrey S Dome; Amrita Das; Thomas J Carroll; Harold N Lovvorn
Journal:  Pediatr Blood Cancer       Date:  2013-09-20       Impact factor: 3.167

7.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

8.  Association of FOXM1 expression with tumor histology and prognosis in Wilms tumor: Potential for a new prognostic marker.

Authors:  Nadja Apelt; Jochen Hubertus; Doris Mayr; Norbert Graf; Rhoikos Furtwängler; Dietrich Von Schweinitz; Roland Kappler
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

Review 9.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.

Authors:  Lauren N Parsons; Elizabeth A Mullen; James I Geller; Yueh-Yun Chi; Geetika Khanna; Richard D Glick; Jennifer H Aldrink; Kelly L Vallance; Yeonil Kim; Conrad V Fernandez; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2020-04-08       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.